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ABSTRACT 
Introduction Myopia is a worldwide epidemic. Plethora of treatments are offered to decrease 
myopia progression. In this study, we compared between different geographical areas worldwide 
the practice patterns used by paediatric ophthalmologists to decrease the progression of myopia. 
Methods Global responses to a questionnaire were analysed (n=794) for demographic variations. 
Pharmacological, optical and behavioural categories were defined as effective or ineffective 
based on the current scientific peer reviewed literature. 
Results Treatment rates varied significantly between geographical regions (mean 57%, range 
39%–89%, p<0.001). Nearly all participants who treat myopia used at least one form of effective 
treatment, regardless of location (98%, p=0.16). Among those prescribing pharmacological 
treatments, European physicians offered the lowest rate of effective treatment compared with 
other regions (85% vs mean 97%). Rates of effective optical treatment varied significantly 
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between locations (p<0.001), from 16% (Central-South America) to 56% (Far East). Most treating 
respondents advocated behavioural modifications (92%), between 87% (North America) and 
100% (Central Asia). Nearly all respondents used combinations of treatment modalities (95%)—
mostly pharmacological, optical and behavioural combination. However, combination rates varied 
significantly between regions (p<0.001). 
Discussion The utility of treatment to decrease myopia progression differs significantly across 
the world both in type, combination and efficacy. 
Conclusion Paediatric ophthalmologists involvement and proficiency in myopia progression 
treatment varies around the world. This may entail promoting continuous medical education and 
other incentives to increase the number and proficiency of paediatric ophthalmologist to have a 
more effective impact to control the myopia epidemic in children. 
Keywords: child health (paediatrics); optics and refraction; public health; treatment medical 
 
 
 
INTRODUCTION 
Myopia is a well-known cause of ocular morbidity and is considered to be a major risk 
factor for vision impairment and sight-threatening complications.1 2 Myopia is the most 
common visual disorder with increasing prevalence rates worldwide. Lately, the WHO has 
declared myopia as an epidemic.3 The magnitude of the phenomena and socioeconomic 
burden derived from this condition led to the development of various strategies to control 
myopia by either pharmacological, behavioural or optical measures. Although a 
consensus regarding the best treatment approach has not yet been determined, several 
treatments were proven to be effective.4 5 However, in absence of an official treatment 
protocol, there is a wide variation in treatment patterns among paediatric 
ophthalmologists who have chosen to treat children and teenagers to decrease myopia 
progression.6 
The purpose of this study was to map the practice patterns to control myopia progression 
in the different world regions. 
 
 
METHODS 
DATA COLLECTION 
Responses regarding the approach to control myopia progression were collected from 
paediatric ophthalmologists worldwide using an online survey between December 2016 
and June 2017 as outlined previously.6 The questionnaire included 17 questions related 
to characteristics of the paediatric ophthalmologists, the myopic patient population and 
choice of treatment modalities to halt the progression of myopia. 
EFFECTIVE TREATMENT DEFINITION 
Treatments were deemed effective or ineffective  based on a previous analysis as long 
as they statistically significantly decreased the progression of myopia.4 5 7–12 Treatments 
derived from online responses were divided into three categories: pharmacological, 
optical or behavioural. For every respondent, each treatment group was classified as 
effective if the respondent employed at least one effective method within that group to 
reduce myopia progression. 
Table 1 
Characteristics of participants treating myopia 
Region 
North 
America 
(n=151) 
Central-
South 
America 
(n=47) 
Europe 
(n=51) 
Middle 
East 
(n=34) 
Central 
Asia 
(n=65) 
Far 
East 
(n=91) 
Australia 
(n=16) 
Total 
(n=455) 
P 
value 
Affiliation 
University 
hospital 
49 17 24 20 22 49 9 190 
0.004 32.5% 36.2% 47.1% 58.8% 33.8% 53.8% 56.3% 41.8% 
Other 102 30 27 14 43 42 7 265 
 
 
Region 
North 
America 
(n=151) 
Central-
South 
America 
(n=47) 
Europe 
(n=51) 
Middle 
East 
(n=34) 
Central 
Asia 
(n=65) 
Far 
East 
(n=91) 
Australia 
(n=16) 
Total 
(n=455) 
P 
value 
67.5% 63.8% 52.9% 41.2% 66.2% 46.2% 43.8% 58.2% 
Years in practice 
0–5 
19 4 4 7 12 22 2 70 
0.02 
12.7% 8.5% 7.8% 20.6% 18.5% 24.2% 13.3% 15.5% 
5–10 
19 7 9 6 13 18 1 73 
12.7% 14.9% 17.6% 17.6% 20.0% 19.8% 6.7% 16.1% 
10–15 
14 8 9 9 16 13 3 72 
9.3% 17.0% 17.6% 26.5% 24.6% 14.3% 20.0% 15.9% 
15–20 
21 7 9 6 11 13 1 68 
14.0% 14.9% 17.6% 17.6% 16.9% 14.3% 6.7% 15.0% 
20–25 
31 7 8 4 8 11 3 72 
20.7% 14.9% 15.7% 11.8% 12.3% 12.1% 20.0% 15.9% 
>25 
46 14 12 2 5 14 5 98 
30.7% 29.8% 23.5% 5.9% 7.7% 15.4% 33.3% 21.6% 
 
 
Region 
North 
America 
(n=151) 
Central-
South 
America 
(n=47) 
Europe 
(n=51) 
Middle 
East 
(n=34) 
Central 
Asia 
(n=65) 
Far 
East 
(n=91) 
Australia 
(n=16) 
Total 
(n=455) 
P 
value 
Experience in myopia treatment (years) 
1–2 
81 24 18 18 17 26 7 191 
<0.001 
54.7% 51.1% 35.3% 56.3% 26.6% 28.6% 43.8% 42.5% 
3–5 
38 11 16 10 18 26 8 127 
25.7% 23.4% 31.4% 31.3% 28.1% 28.6% 50.0% 28.3% 
6–10 
11 8 9 1 14 14 1 58 
7.4% 17.0% 17.6% 3.1% 21.9% 15.4% 6.3% 12.9% 
>10 
18 4 8 3 15 25 0 73 
12.2% 8.5% 15.7% 9.4% 23.4% 27.5% 0.0% 16.3% 
 
STATISTICAL ANALYSIS 
Data were analysed by statistical analysis software (IBM SPSS for windows, V.25). 
Significance was defined as an alpha error probability <0.05. The χ² test was used for 
comparison of categorical variables and Student's t-test and one-way analysis of variance 
(ANOVA) were used for comparison of continuous variables. Linear and binary logistic 
regressions analysis were applied as needed to detect interactions between variables 
and exclude confounder effects. 
 
 
All authors declared no financial or non-financial conflict of interest, and no formal 
consents were required as the information obtained through the questionnaire did not 
refer to a specific patient but rather to the general clinical treatment patterns of the treating 
ophthalmologist. 
The study adhered to the principles outlined in the Declaration of Helsinki and was 
approved by the local institutional review board (IRB) at Sheba Medical Center, Tel 
Hashomer, Israel. 
 
RESULTS 
RESPONDENT'S CHARACTERISTICS 
Of the 794 responses received from paediatric ophthalmologists worldwide, 455 (57.3%) 
were from those who have chosen to treat to reduce the progression of myopia. The 
responses were grouped into seven geographical regions (figure 1). The relative size of 
groups from various geographical regions varied significantly between all the respondents 
and those that treat to reduce myopia progression. Physicians from North America and 
the Far East comprised a larger part of the treating group than in the group of all the 
respondents. In contrast, the relative part of physicians from Europe in the treating group 
was smaller than in all the respondents. Distribution of university affiliation, overall 
duration of experience to treat to reduce myopia progression and length of practice in 
years were similar to that of the general cohort. 
 
 
 
FIGURE 1 
DISTRIBUTION OF RESPONDENTS BY GEOGRAPHICAL REGION. 
Respondents’ characteristics are summarized in table 1. North American 
ophthalmologists comprised the largest group (151, 33.2%) followed by the Far East (91, 
20%), Central Asia (65, 14.3%), Europe (51, 11.2%) and Central and South America (47, 
10.3%). Most respondents have been practicing ophthalmology for more than 10 years. 
However, the distribution of the duration of clinical practice varied significantly (p=0.020) 
between regions. The highest rate of physicians practicing over 15 years was reported in 
Central-Asia (96, 82.1%) and lowest in Australia (8, 47.1%). Overall 190 (41.8%) 
respondents were affiliated to university hospitals with significant variation in prevalence 
between geographical regions (p=0.004), ranging from 32.5% (49) in North-America to 
56.3% (9) in Australia. 
Initiation of treatment 
Indications for initiation of treatment were described by 319 of respondents (70% of 
respondents that treat myopia) and varied between regions (figure 2). The most common 
indication for treatment all over the world as well as in each geographical region was the 
rate of myopia progression (diopter/year (D/y)) (239, 75% of respondents). 
 
 
 
Figure 2 
Variations between respondents from different geographical regions in 
implementation of criteria for initiation of treatment to reduce myopia progression. 
On average, a progression rate of 1.1±0.6 D/y was chosen overall as the cut-off for 
initiation of treatment with minor deviations across regions (range 0.90–1.25, p=0.537). 
Eighty-five respondents (27%) started treatment when they identified a refractive error of 
−2.7±1.8 D or more. The degree of myopia to start treatment varied between regions. The 
cut-off was significantly (p<0.05) lower among those from the Far East (1.37±1.6) 
compared with North American (3.36±1.67) and Central-South America (−3.61±2.26) 
despite the similar prevalence in implementation of the criteria in those geographical 
regions (32% and 33%, respectively). The age cut-off did not differ significantly between 
regions (ANOVA, p=0.062) with an overall mean of 5.33±1.35 years. However, the 
prevalence of physicians who started treatment according to the age myopia was first 
detected differed between regions: 30% in Central-South America to 7.4% in Central Asia 
(p=0.065). 
TREATMENT MODALITIES 
Most respondents treating myopia (449, 99%) selected the modality they considered to 
be most effective. Responses varied significantly between regions (p<0.001). 
 
 
Pharmacological treatment was the most popular modality in most regions apart from 
Europe and Central Asia where optical treatment was preferred (figure 3). Respondents 
who initiated treatment when the rate of progression increased beyond their cut-off criteria 
selected pharmacological treatment at a significantly higher rate than those who did not 
choose that criteria (81% vs 59%, p<0.001). In addition, the progression rate cut-off 
selected by physicians preferring the optical modality of treatment was significantly higher 
compared with the cut-off level chosen by those who opted for the pharmacological or 
behavioural treatment (2.0±1.0 D/y vs 1.1±0.5 and 1.1±0.4 D/y, respectively, p<0.001). 
Respondents who initiated treatment for any degree of myopia preferred pharmacological 
treatment significantly less than those who did not apply the level of myopia as a criterion 
(57% vs 80%, p=0.002). 
 
Figure 3 
Variations between respondents from different geographical regions in the 
prevalence of modalities to reduce myopia progression. 
Pharmacological treatment 
Pharmacological treatment was used by 313 (68.8%) respondents treating myopia 
progression. The prevalence of physicians using a pharmacological treatment varied 
significantly (p<0.001) between regions (online supplementary table 3). Pharmacological 
 
 
treatment was significantly more popular among physicians treating myopia for 1–2 years 
or those with less than 15 years overall of clinical experience (online supplementary table 
3). 
Only pharmacological treatments with either atropine (all dosages) or pirenzepine were 
deemed effective (table 1). 
The prevalence of physicians prescribing effective pharmacological treatments was 97% 
(n=303) overall. It was 93% or higher in most regions, but lower in Europe (22/26, 85%). 
An effective pharmacological treatment was prescribed by respondents who have chosen 
an optical treatment as the most effective modality at a significantly lower rate (20/26, 
77%) compared with respondents who have chosen a behavioural modality (43/46, 
93.5%) or a pharmacological modality (236/237, 99.6%) (p<0.001). Physicians who had 
initiated treatment according to a specific age at which myopia was first detected choose 
an effective treatment significantly less compared with those using other indications 
(50/55, 91% vs 248/253, 98%, p=0.007). In contrast, physicians who initiated a treatment, 
when the rate of myopia progression exceeded a cut-off, used an effective treatment more 
than those using other indications (228/233, 98% vs 70/75, 93%, p=0.055). 
OPTICAL TREATMENT 
The cohort included 405 (89%) respondents using optical treatment to decrease myopia 
progression. The prevalence of physicians using optical treatment varied significantly 
among geographical regions (p=0.010). It was most popular in Europe (48, 94.1%), 
Central-Asia (62, 95.4%), Central-South America (45, 95.7%) and the Far-East (84, 
92.3%) and less popular in North-America (126, 83.4%), Australia (12, 75%) and the 
Middle-East (28, 82.4%). The prevalence was higher among respondents who were not 
affiliated to a university hospital (243/265, 91.7% vs 162/190, 85.3%, p=0.030). The 
prevalence was also higher among those considering the optical modality to be the most 
effective (92/93, 98.9%) compared with respondents considering pharmacological 
(214/251, 85.35) or behavioural (97/105, 92.4%) modalities to be most effective, 
p=0.001). 
 
 
Overall, only 157 (38.8%) of respondents using an optical treatment used an effective 
optical method. The prevalence of paediatric ophthalmologists using effective optical 
treatment varied significantly between regions (range 7/38, 15.6% in Central-South 
America to 47/84, 56% in the Far-East). Ophthalmologists with over 10 years of 
experience in myopia treatment used effective optical treatments at a significantly higher 
rate compared with less experienced ophthalmologists (42/28, 60% vs 112/332, 33.7%, 
p<0.001). The use of an effective optical treatment was also significantly higher among 
those considering the optical modality to be most effective compared with physician who 
preferred one of the other two modalities (49/92, 53.3% vs 107/311 34.4%, p=0.001). 
Additionally, there was a higher prevalence of physicians who offered an effective optical 
treatment among those that started treatment when myopia reached a certain threshold, 
in contrast to other criteria (p=0.007). 
BEHAVIOURAL TREATMENT 
Among the three treatment modalities, behavioural treatment was used by the highest 
number of respondents (414, 92.2%). Again, the prevalence varied significantly between 
regions from 86% (130/151) in North-America to 98% (89/91) and 100% (65/65) in the 
Far-east and Central-Asia, respectively (p=0.004). No other factors were found to 
significantly affect the prevalence of behavioural treatment implementation. 
COMBINATION OF MODALITIES 
Most respondents used a combination of either two (174, 38%) or three modalities of 
treatment (255, 56%). The histogram in figure 4 depicts the distribution of applied 
treatment modalities and combinations according to geographical regions. A combination 
of all three modalities was the most popular in most regions apart from Central-Asia where 
the prevalence of optical and behavioural combinations was higher. The optical and 
behavioural combination was the second most popular in most places excluding North-
America and Australia. This combination was also used significantly more by physicians 
affiliated to an academic hospital (58/190, 30.5% vs 66/265, 24.9%). In contrast, the triple-
modality-combination was less popular among academically affiliated physicians (93/190, 
48.9% vs 162/265, 61.1%, p=0.018). The prevalence of triple-modality-combination was 
much higher among physicians who had deemed the pharmacological modality to be the 
 
 
most effective (189/251, 75.3%) compared with those who had opted for optical (23/93, 
24.7%) or the behavioural (41/105, 39%) as most effective (p<0.001). The distribution of 
the preference of treatment combination was not correlated with the amount of years in 
practice, experience in treating myopia progression or any specific indication for initiation 
of treatment. 
 
Figure 4 
Variations between respondents from different geographical regions in prevalence 
of combinations of modalities to reduce myopia progression. 
The prevalence of physicians using an effective pharmacological or optical treatment did 
not differ significantly whether they used a single or multiple treatment modalities. 
DISCUSSION 
Myopia is a growing concern among ophthalmologists worldwide.3 Although many types 
of medical interventions have been proposed to decrease myopia progression, only few 
 
 
have been proven to be effective. In this study, we attempted to describe compare 
between the real-life practice patterns of paediatric ophthalmologists around the world. 
Significant variability in myopia treatment choices was observed. It was affected by the 
geography, clinical experience and more specifically, experience in treating myopia 
progression. 
According to our data, paediatric ophthalmologists who treat myopia progression were 
usually experienced physicians with over 15 years of clinical practice, although most have 
been treating myopia for less than 5 years. This discrepancy could be due to both the 
growing awareness of the myopia epidemic in recent years3 and the emergence of 
multiple studies regarding the various treatment options. These observations indicate that 
awareness of importance to treat myopia progression might be lacking both among young 
and seasoned paediatric ophthalmologist. Most treating physicians, who have responded 
to the questionnaire, were not affiliated to a university hospital, similar to the percentage 
among all the respondents. As previously reported by our group,6 we observed a 
significant difference in treatment rates between geographical regions, yet this difference 
did not seem to be related to either affiliation or to number of years in practice. 
Despite the lack of consensus in the literature when to initiate treatment,5 the results from 
our survey show that the vast majority of physicians use a myopia progression rate of ~1 
D/y as the main guideline, with minor regional variations (figure 2). In contrast, there were 
greater geographical variations in the criteria based on the degree of myopia or the age 
myopia was first detected. This was evident both in prevalence of use and refractive or 
age cutoffs. Paediatric ophthalmologists from Central-Asia and the Far-East Asia chose 
a significantly lower myopic refractive error cut-off compared with all other regions. This 
might be due to the high prevalence of myopia in those regions.3 13 14 The relatively high 
prevalence of initiation of treatment at the first sign of any degree of myopia in these 
regions support this practice pattern. 
The use of pharmacological modalities varied significantly between regions. Overall, it 
was significantly more popular among newer physicians and among those who more 
recently started to treat myopia, probably due to a higher utility of educational material to 
improve knowledge among physician new to the field. These results may explain in part 
 
 
the relatively high prevalence of pharmacological treatment observed among physicians 
in North-America and Australia from which there was a high rate of respondents with a 
short experience in myopia treatment and few years of clinical practice. The vast majority 
of physicians in all the regions promoting a pharmacological treatment choose an 
effective pharmacological drug. Respondents from around the world, that chose 
pharmacological treatment as the most effective modality, used this modality effectively 
much more frequently. Pharmacological treatment was least popular among European 
physicians. Furthermore, less of them offered an effective pharmacological treatment 
compared with all the other regions (85% vs 93%). This might be due to the fact most 
studies were conducted in Asia in Chinese children, raising a concern these data might 
be less applicable to Caucasians.2 15–17 It should be noted that despite the growing 
evidence in the literature that supports the use of atropine to decrease myopic 
progression,17–21 pharmacological treatments were not used by almost a third of 
respondents treating myopia progression. 
The popularity of employing optical treatments varied significantly between regions. The 
relatively lower rate among physicians from North-America and Australia corresponds to 
the higher rates of pharmacological treatments in these regions. More importantly, 
considerably less respondents prescribed effective optical treatments than effective 
pharmacological treatments, with significant variation between regions. It is apparent that 
higher rates of applied optic treatments did not necessarily mean a high rate of using an 
effective optical treatment (eg, a 95.7% administration rate in Central-South America of 
which only 15.6% were effective). The large variation between regions and low rate of 
efficient treatment might stem from the lack of continued medical education (CME) of 
paediatric ophthalmologist regarding the best effective optical treatment alternatives. An 
additional factor is the availability and popularity of optical solutions that improve visual 
acuity without decreasing myopic progression, for example, monofocal eyeglasses 
instead of progressive addition lenses. Respondents who have selected optical modality 
as the most effect treatment option also significantly used optical treatments at a higher 
rate and choose a more effective treatment. The prevalence of offering an optical modality 
was significantly higher among physicians not affiliated to a university hospital. However, 
the rate of choosing effective optical treatments was similar between respondents who 
 
 
were affiliated to university hospitals and those who were not. Clinical experience was 
also associated with an increased rate of using effective optical treatments. 
Behavioural treatment was the most popular modality used by over 90% of respondents. 
There is ample evidence regarding the association between behavioural risk factors (eg, 
increased near visual activity, sedentary posture or reduced time outdoors) and myopia 
progression.17 22–24 The prevalence of the use of this modality was significantly higher in 
Far East Asia, where behavioural risk factors were shown to play a major role in myopia 
development.17 Taking preventive measures might have made this modality popular as a 
first-line inexpensive and available treatment as opposed to both the pharmacological 
and optical modalities that offer interventional measures. 
The majority of physicians across all regions used two or more modalities, most probably 
owing to the lack of consensus as to which modality is most effective and possible 
synergistic effects of these combinations.25 We also observed a significantly higher 
prevalence of the combing pharmacological, optical and behavioural treatments by 
physicians who had deemed the pharmacological modality to be the most effective. This 
may suggest that these respondents were more familiar with current literature 
recommendations. 
In conclusion, in this study, we found marked variation in the practice patterns to decrease 
myopia progression around the world. Although there are not any clear guidelines for 
initiation of treatment, our survey found a relative global consensus regarding initiating 
treatment when myopia progresses at a rate of 1 D/y. Treatment selection of effective 
measures differed greatly between regions. The differences were most apparent in the 
use of optic treatments where a plethora of options most of which are ineffective lead to 
maltreatment to control myopia. In our survey, physicians who were familiar with 
pharmacological treatments also knew when to initiate treatment and used much more all 
three modalities. It is not surprising, however, that many respondents did not know how 
to effectively treat myopia progression, probably due to lack of CME. In order to alter the 
expanding myopia epidemic, we advocate that treatment recommendation criteria and 
guidelines be made by national as well as supranational medical organisations. Many 
 
 
more national public health programmes26 should advance and disseminate this 
information to practicing paediatric ophthalmologists by different means such as CME. 
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